Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.

13.05 0.15 +1.16%
Market cap
$10.7B
P/E
32.9×
Fwd P/E
24.3×
Dividend yield
0.00%
F-score
4/9
Altman Z
5.26
Beneish M
−2.59
Dividend safety
74/100

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
3,148.00 3,312.00 3,219.00 3,162.00
Total non-current assets
2,957.00 2,954.00 2,956.00 2,915.00
Total Assets
6,105.00 6,266.00 6,175.00 6,077.00
Total current liabilities
1,700.00 1,762.00 1,787.00 1,661.00
Total non-current liabilities
327.00 321.00 334.00 330.00
Total liabilities
2,027.00 2,083.00 2,121.00 1,991.00
Common Equity (Total)
4,077.00 4,183.00 4,054.00 4,085.00
Shareholders Equity (Total)
4,078.00 4,183.00 4,054.00 4,086.00
Total Debt
660.00 754.00 824.00 760.00

Show all line items

In millions of $ except per-share values · columns are period end dates